EI
RIGL icon

EAM Investors’s Rigel Pharmaceuticals RIGL Stock Holding History

EAM Investors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,983
Closed -$1.16M – 360
2025
Q4 		$1.16M Sell
26,983
-8,932
-25% -$337K 0.13% 196
2025
Q3 		$1.02M Buy
+35,915
New +$1.07M 0.12% 192
2018
Q1 		– Sell
-22,364
Closed -$868K – 348
2017
Q4 		$868K Buy
+22,364
New +$851K 0.16% 222
2016
Q4 		– Sell
-69,504
Closed -$2.55M – 353
2016
Q3 		$2.55M Buy
+69,504
New +$1.99M 0.34% 166

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors's RIGL Position: Q1 2026 in Review

EAM Investors sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 26,983 shares — an estimated $1.16M sold.

EAM Investors first reported a position in RIGL in Q3 2016 and held it in 4 quarters. The position peaked at $2.55M in Q3 2016. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • EAM Investors reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • EAM Investors sold 26,983 Rigel Pharmaceuticals shares in Q1 2026, an estimated $1.16M.
  • EAM Investors first reported a position in Rigel Pharmaceuticals in Q3 2016 and held it in 4 quarters.
  • EAM Investors's Rigel Pharmaceuticals position peaked at $2.55M in Q3 2016.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.